 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...2627282930313233343536...123124» |
- Keytruda (pembrolizumab) / Merck (MSD)
Hand-foot syndrome induced by Pembrolizumab for non-small cell lung cancer (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2365;
HFS has been described in the literature as an uncommon side effect of many anti-tumor drugs including pembrolizumab but always in combination with other drugs such as capecitabine, lenvatinib and anlotinib. There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer.
- ||||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment change, Combination therapy: EMERALD-3: Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC (clinicaltrials.gov) - Aug 29, 2023
P3, N=725, Recruiting, Sponsor: AstraZeneca
There are no reports in literature concerning the development of HFS as side effect of pembrolizumab in monotherapy, thus our report may help researcher to improve the side effect profile of the immunotherapeutic agent that is nowadays considered a novel and encouraging tool against cancer. N=525 --> 725
- | Enrollment closed, Metastases: Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy (clinicaltrials.gov) - Aug 28, 2023
P2, N=32, Active, not recruiting, Sponsor: Institut f
N=525 --> 725 Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Neoantigen Derived DCs as Cancer Treatment (clinicaltrials.gov) - Aug 25, 2023
P1, N=12, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Outcome of initial lenvatinib treatment in patients with unresectable anaplastic thyroid cancer. (Pubmed Central) - Aug 24, 2023
Two patients, who showed a reduction with lenvatinib, underwent conversion surgery, which prolonged the prognosis in terms of avoiding events, such as asphyxia, fistula and hemorrhage due to tumor growth; however, the surgical margins were positive, indicating that complete remission was impossible even if surgical resection was performed. Therefore, starting with lenvatinib treatment and identifying a therapeutic drug based on genomic analysis is an acceptable treatment strategy for ATC while halting the disease progression.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors (clinicaltrials.gov) - Aug 24, 2023
P2, N=35, Recruiting, Sponsor: Zhejiang Cancer Hospital
Therefore, starting with lenvatinib treatment and identifying a therapeutic drug based on genomic analysis is an acceptable treatment strategy for ATC while halting the disease progression. Not yet recruiting --> Recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Aug 24, 2023
P1, N=11, Active, not recruiting, Sponsor: Yousef Zakharia
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| Stivarga (regorafenib) / Bayer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Journal, Adverse events: Cardiovascular toxicities following the use of tyrosine kinase inhibitors in Hepatocellular Cancer Patients: A Retrospective, Pharmacovigilance Study. (Pubmed Central) - Aug 23, 2023
A total of 4708 cardiac AEs reports of sorafenib, regorafenib, lenvatinib and cabozantinib were identified...Analysis of FAERS data provides a precise profile on the characteristics of cardiac AEs associated with different TKI regimens. Distinct monitoring and appropriate management are needed in the care of TKI recipients.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Sutent (sunitinib) / Pfizer
The Role of Stereotactic Radiotherapy in Deferring the Need for Systemic Therapies in Patients with Progressive Oligometastatic Iodine-Refractory Thyroid Cancer (Hall B2; In Person Only) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_2183;
Eleven patients (50%) needed to start TKI treatment (6 Lenvatinib, 3 Sunitinib and 2 Sorafenib) for progressive disease: median time to first systemic treatment from SRT was 18,5 months (range 0,5-67 months). In our experience, SBRT yields satisfying local control rates in oligometastatic Iodine-refractory DTC, potentially allowing for a deferral of systemic therapies, and should always be considered in these patients.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Beneficial Role of Multi-Disciplinary Treatment for Anaplastic Thyroid Cancer with Initial Distant Metastasis (Hall B2; In Person Only) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_2169;
Local treatment combined with chemotherapy for M1 ATC patients showed outcome comparable to those of non-metastatic ATC results. Active local treatment should be considered especially for patients with less than 10 metastases, and patients without distant progression in early response evaluation.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
Safety and Efficacy of Hypofractionated Radiotherapy Combined with Tyrosine Kinase Inhibitors in Patients with Lung Metastases after Liver Transplantation for Hepatocellular Carcinoma (Hall B2; In Person Only; Screen: 34) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_1393;
Materials/ Twenty-five patients with lung metastases after OLT for HCC who underwent HFRT using helical tomotherapy concomitantly with TKIs (sorafenib or lenvatinib) were retrospectively. The combination therapy of HFRT with TKIs is a feasible, safe, and promising approach in the treatment of pulmonary metastases for HCC after OLT.
- Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases (Hall B2; In Person Only; Screen: 11) - Aug 22, 2023 - Abstract #ASTRO2023ASTRO_663;
Although heterogeneous, patients treated with SRS/SRT and ongoing CNS-active targeted systemic therapies have on average >6 month intracranial PFS and little evidence of significant toxicity. We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis.
- || E7386 / Eisai, PRISM Pharma
Trial completion date, Trial primary completion date: E7386-J081-102: A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (clinicaltrials.gov) - Aug 22, 2023
P1b, N=181, Recruiting, Sponsor: Eisai Inc.
We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis. Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Oct 2024
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P4 trial: A Clinical Study of Tislelizumab Combined With TACE and Lenvatinib in the Neoadjuvant Treatment of Resectable HCC (clinicaltrials.gov) - Aug 22, 2023
P4, N=20, Not yet recruiting, Sponsor: First Affiliated Hospital of Fujian Medical University
- | zabinostat (CXD101) / IngenOx Therap, Nuance Biotech
Enrollment open, Checkpoint inhibition: CXD101 in Immunotherapy-related Liver Cancer (clinicaltrials.gov) - Aug 22, 2023
P2, N=44, Recruiting, Sponsor: Stephen Chan Lam
Trial completion date: Jan 2025 --> Oct 2024 | Trial primary completion date: Jan 2025 --> Oct 2024 Not yet recruiting --> Recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: circFAM134B is a key factor regulating reticulophagy-mediated ferroptosis in hepatocellular carcinoma. (Pubmed Central) - Aug 21, 2023
In the current study, we found that the homologous circular RNA (circRNA) of the family with sequence similarity 134, member B (FAM134B), hsa_circ_0128505 (was abbreviated as circFAM134B in the present study), was identified to specifically target ER-phagy to promote lenvatinib (LV)-induced ferroptosis using reactive oxygen species (ROS), Fe, malondialdehyde (MDA), and western blot (WB) assays in HCC cells...circFAM134B was confirmed as a sponge that competitively interacted with PABPC4, thereby influencing FAM134B mRNA nonsense decay. Our results provide novel evidences and strategies for the comprehensive treatment of HCC.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal, Metastases: Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study. (Pubmed Central) - Aug 21, 2023
Furthermore, radiomic features were associated with overall survival and progression-free survival both in the training and validation cohorts, but modified albumin-bilirubin grade and neutrophil-to-lymphocyte ratio were not. Radiomic features extracted from pretreatment MRI can predict individualized objective response to combination therapy with lenvatinib plus an anti-PD-1 antibody in patients with unresectable or advanced HCC, provide incremental predictive value over clinicopathologic features, and are associated with overall survival and progression-free survival after initiation of this combination regimen.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Lenvatinib for Advanced Bone and Soft Tissue Sarcoma (clinicaltrials.gov) - Aug 21, 2023
P2, N=60, Recruiting, Sponsor: Henan Cancer Hospital
Radiomic features extracted from pretreatment MRI can predict individualized objective response to combination therapy with lenvatinib plus an anti-PD-1 antibody in patients with unresectable or advanced HCC, provide incremental predictive value over clinicopathologic features, and are associated with overall survival and progression-free survival after initiation of this combination regimen. Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal, Combination therapy: The Analysis of Muscle Volume Measured by Bioelectrical Impedance in Patients with Hepatocellular Carcinoma Treated with First-Line Atezolizumab plus Bevacizumab Combination Therapy or First-Line Lenvatinib. (Pubmed Central) - Aug 21, 2023
Not yet recruiting --> Recruiting Assessing body composition with BIA before Atezo + Beva and Len treatment may be useful.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: Lenvatinib and Pembrolizumab in People with Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers (clinicaltrials.gov) - Aug 18, 2023
P2, N=64, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Assessing body composition with BIA before Atezo + Beva and Len treatment may be useful. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. (Pubmed Central) - Aug 17, 2023
With the advancement of ICIs, it is anticipated that the role of MKIs in the treatment of HCC will evolve. In this article, lenvatinib, one of the most commonly used MKIs in HCC, is chosen to be reviewed.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Enrollment change, Surgery, Metastases: Chemoradiation and Pembrolizumab Followed by Pembrolizumab and Lenvatinib Before Surgery for the Treatment of Non-metastatic Esophageal or Esophageal/Gastroesophageal Junction Cancer (clinicaltrials.gov) - Aug 16, 2023
P2, N=3, Active, not recruiting, Sponsor: City of Hope Medical Center
In this article, lenvatinib, one of the most commonly used MKIs in HCC, is chosen to be reviewed. Recruiting --> Active, not recruiting | N=24 --> 3
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Syntaxin-6 promotes the progression of hepatocellular carcinoma and alters its sensitivity to chemotherapies by activating the USF2/LC3B axis. (Pubmed Central) - Aug 15, 2023
This study revealed that, under the control of USF2, STX6 accelerates the degradation of microtubule-associated protein 1 light chain 3 beta (LC3) by promoting autophagic flux, ultimately promoting HCC progression. Collectively, we suggest that the USF2-STX6-LC3B axis is a potential therapeutic target in liver cancer.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lnc-ZEB2-19 Inhibits the Progression and Lenvatinib Resistance of Hepatocellular Carcinoma by Attenuating the NF-?B Signaling Pathway through the TRA2A/RSPH14 Axis. (Pubmed Central) - Aug 15, 2023
Furthermore, rescue assays showed that silencing RSPH14 partially restrained the effect of knockdown expression of lnc-ZEB2-19 on HCC cell metastatic ability and stemness. The findings describe a novel regulatory axis, lnc-ZEB2-19/TRA2A/RSPH14, downregulating the nuclear factor kappa B to inhibit HCC progression and LR.
- | Tyvyt (sintilimab) / Eli Lilly, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib, Sintilimab Plus SIRT for Unresectable HCC (clinicaltrials.gov) - Aug 15, 2023
P2, N=30, Not yet recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- ||| livmoniplimab (ABBV-151) / AbbVie, budigalimab (ABBV-181) / AbbVie
Enrollment open, Adverse events, Checkpoint inhibition: LIVIGNO-1: Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Aug 15, 2023
P2, N=120, Recruiting, Sponsor: AbbVie
The findings describe a novel regulatory axis, lnc-ZEB2-19/TRA2A/RSPH14, downregulating the nuclear factor kappa B to inhibit HCC progression and LR. Not yet recruiting --> Recruiting
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: ZSAB-TransGOLP: Tislelizumab?Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer (clinicaltrials.gov) - Aug 15, 2023
P2, N=40, Active, not recruiting, Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Oct 2022 --> Jul 2023
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Sophoridine derivative 6j inhibits liver cancer cell proliferation via ATF3 mediated ferroptosis. (Pubmed Central) - Aug 14, 2023
Further study revealed that compound 6j upregulated the expression of ATF3 via ER stress and knockdown of ATF3 by RNA interference attenuated 6j induced ferroptosis and cell proliferation inhibition. This study would provide new insights for the design of ferroptosis inducers and the development of anti-liver cancer drugs.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence. (Pubmed Central) - Aug 14, 2023
This study would provide new insights for the design of ferroptosis inducers and the development of anti-liver cancer drugs. We then initiated chemotherapy treatment with lenvatinib at 8
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Combination therapy, Checkpoint inhibition, Metastases: Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma. (Pubmed Central) - Aug 14, 2023
Patients with favorable risk or treated earlier may have a better treatment response. These observations need to be confirmed in prospective studies.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
PK/PD data, Preclinical, Journal: Differences in the pharmacokinetics and steady-state blood concentrations of orally administered lenvatinib in adult and juvenile rats. (Pubmed Central) - Aug 14, 2023
Juvenile rats exhibit lower levels of lenvatinib in the liver's steady-state, potentially due to the disparity in CYP3A2 mRNA expression. These results imply that the dosage of lenvatinib for pediatric patients may need to be augmented in order to attain the desired clinical outcome.
- | Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date, Trial primary completion date, Metastases: MK-3475-A70: Pembrolizumab and Lenvatinib in Advanced Cervical Cancer (clinicaltrials.gov) - Aug 14, 2023
P2, N=35, Recruiting, Sponsor: Georgetown University
These results imply that the dosage of lenvatinib for pediatric patients may need to be augmented in order to attain the desired clinical outcome. Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024
- | Tevimbra (tislelizumab-jsgr) / BeiGene, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change: PREVENT-2: Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (clinicaltrials.gov) - Aug 14, 2023
P3, N=200, Not yet recruiting, Sponsor: Guangxi Medical University
Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024 N=300 --> 200
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), simridarlimab (IBI-322) / Innovent Biologics
Biomarker, New trial, Combination therapy, Real-world evidence, Real-world: Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - Aug 14, 2023
P=N/A, N=160, Not yet recruiting, Sponsor: Hunan Province Tumor Hospital
- | Tyvyt (sintilimab) / Eli Lilly, Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P3 trial, Metastases: Sintilimab+Bevacizumab+TACE vs. Lenvatinib+TACE for Advanced HCC (clinicaltrials.gov) - Aug 14, 2023
P3, N=258, Recruiting, Sponsor: Second Affiliated Hospital of Guangzhou Medical University
- ||||| Welireg (belzutifan) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Metastases: LITESPARK-011: A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) (clinicaltrials.gov) - Aug 14, 2023
P3, N=708, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
N=300 --> 200 Recruiting --> Active, not recruiting
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Efficacy and safety of transarterial chemoembolization combined with lenvatinib, programmed death-1 inhibitor, and iodine-125 seed brachytherapy for hepatocellular carcinoma with portal vein tumor thrombosis. (Pubmed Central) - Aug 13, 2023
Recruiting --> Active, not recruiting A combination therapy of TACE, lenvatinib, programmed death-1 inhibitor, and I125 seed brachytherapy significantly improve OS, PFS, and DCR and show better survival prognosis for HCC patients accompanied by PVTT.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD), Tecentriq (atezolizumab) / Roche
Journal: Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma. (Pubmed Central) - Aug 12, 2023
A combination therapy of TACE, lenvatinib, programmed death-1 inhibitor, and I125 seed brachytherapy significantly improve OS, PFS, and DCR and show better survival prognosis for HCC patients accompanied by PVTT. MCT is may effective in patients with BCLC stage C HCC and intrahepatic target nodules who have previously received systemic therapy-based treatment.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFR? complex in hepatocellular carcinoma. (Pubmed Central) - Aug 11, 2023
Furthermore, the combination of an optimal dose of lenvatinib and an anti-PD-1 antibody robustly suppressed tumor growth. Our study proposes a mechanism that explains how the optimal dose of lenvatinib induces vascular normalization and confirms its enhanced synergistic effect with ICBs.
- || Clinical, Retrospective data, Review, Journal: First-line systemic treatment for hepatocellular carcinoma: A systematic review and network meta-analysis. (Pubmed Central) - Aug 10, 2023
Our study proposes a mechanism that explains how the optimal dose of lenvatinib induces vascular normalization and confirms its enhanced synergistic effect with ICBs. Combination of Camrelizumab
- ||| Clinical guideline, Journal: SEOM SOGUG clinical guideline for treatment of kidney cancer (2022). (Pubmed Central) - Aug 9, 2023
In cases that have an intermediate IMDC and poor prognosis, the combination of ipilimumab and nivolumab has demonstrated superior OS compared to sunitinib...When there is progression following initial immunotherapy-based treatment, we recommend treatment with an antiangiogenic tyrosine-kinase inhibitor. While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC (clinicaltrials.gov) - Aug 9, 2023
P2, N=64, Active, not recruiting, Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
While no clear sequence can be advocated, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in the setting of metastatic RC. Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2022 --> Aug 2022
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Transferrin Receptor is Associated with Sensitivity to Ferroptosis Inducers in Hepatocellular Carcinoma. (Pubmed Central) - Aug 7, 2023
Recruiting --> Active, not recruiting | Trial completion date: May 2023 --> Sep 2023 | Trial primary completion date: May 2022 --> Aug 2022 TFR expression is a poor prognostic factor in HCC, but its expression increases sensitivity to ferroptosis-inducing agents.
- | Avastin (bevacizumab) / Roche, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Effect of bevacizumab administered prior to transarterial chemoembolization on the therapeutic effects of lenvatinib given post-TACE in primary liver cancer patients. (Pubmed Central) - Aug 7, 2023
TFR expression is a poor prognostic factor in HCC, but its expression increases sensitivity to ferroptosis-inducing agents. The therapeutic effects of lenvatinib following TACE in primary liver cancer are significantly greater when combined with bevacizumab administered for 6
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal, Real-world evidence, Real-world, Metastases: Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting. (Pubmed Central) - Aug 7, 2023
Median PFS rates were 2.6, 4.4, and 2.8?months in sorafenib-, lenvatinib-, and cabozantinib group, respectively...Regorafenib was associated with better OS and OGS rates compared to other TKI. These data need to be confirmed in prospective comparative studies.
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
P2 data, Journal, Metastases: Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. (Pubmed Central) - Aug 7, 2023
P2
Pembrolizumab plus lenvatinib has durable antitumour activity in patients with previously untreated advanced non-clear-cell renal cell carcinoma, with a safety profile consistent with that of previous studies. Results from KEYNOTE-B61 support the use of pembrolizumab plus lenvatinib as a first-line treatment option for these patients.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial primary completion date, Metastases: Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) (clinicaltrials.gov) - Aug 7, 2023
P3, N=480, Active, not recruiting, Sponsor: Merck Sharp & Dohme LLC
Results from KEYNOTE-B61 support the use of pembrolizumab plus lenvatinib as a first-line treatment option for these patients. Trial primary completion date: Jan 2024 --> Feb 2023
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
SIMULTANEOUS BILATERAL SPONTANEOUS PNEUMOTHORACES IN METASTATIC LUNG CANCER WITH CONCURRENT LENVATINIB USE (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3229;
- MIND THE WEAKNESS: A RARE CASE OF IMMUNE CHECKPOINT INHIBITOR-INDUCED MYASTHENIA GRAVIS (Convention Center Exhibit Hall) - Aug 4, 2023 - Abstract #CHEST2023CHEST_3034;
- CHRONIC PNEUMONITIS DUE TO IMMUNE-CHECKPOINT INHIBITOR IN A PATIENT WITH ENDOMETRIAL CANCER (Convention Center Exhibit Hall - Rapid Area 2D) - Aug 4, 2023 - Abstract #CHEST2023CHEST_774;